Citation Report
List of articles citing

Induction of tolerance in type 1 diabetes via both CD4+CD25+ T regulatory cells and T regulatory type 1 cells

DOI: 10.2337/db05-1576
Diabetes, 2006, 55, 1571-80.

#	Paper	IF	Citations
145	Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. *Immunological Reviews*, **2006**, 212, 28-50	11.3	966
144	Immunosuppression and regulation: cast in new light?. **2006**, 17, 2644-6		8
143	Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. *Journal of Immunology*, **2006**, 177, 8338-47	5.3	566
142	Multimerized T cell epitopes protect from experimental autoimmune diabetes by inducing dominant tolerance. **2007**, 104, 9393-8		13
141	Intravenous transfusion of BCR-activated B cells protects NOD mice from type 1 diabetes in an IL-10-dependent manner. *Journal of Immunology*, **2007**, 179, 7225-32	5.3	100
140	In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. **2007**, 104, 12457-61		93
139	The immune response to lentiviral-delivered transgene is modulated in vivo by transgene-expressing antigen-presenting cells but not by CD4+CD25+ regulatory T cells. **2007**, 110, 1788-96		29
138	Rapamycin impairs in vivo proliferation of islet beta-cells. **2007**, 84, 1576-83		90
137	Converting antigen-specific diabetogenic CD4 and CD8 T cells to TGF-beta producing non-pathogenic regulatory cells following FoxP3 transduction. *Journal of Autoimmunity*, **2007**, 28, 188-200	15.5	25
136	Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. *Journal of Immunology*, **2007**, 178, 7018-31	5.3	358
135	Naturally occurring regulatory T cells: recent insights in health and disease. **2007**, 27, 61-95		61
134	Current literature in diabetes. **2007**, 23, i-xii		
133	Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. *Nature Reviews Immunology*, **2007**, 7, 585-98	36.5	418
132	Immune tolerance and control of CNS autoimmunity: from animal models to MS patients. **2007**, 100, 883-92		24
131	Is FOXP3 a bona fide marker for human regulatory T cells?. **2008**, 38, 925-7		146
130	Regulatory T cells in the past and for the future. **2008**, 38, 901-37		71
129	Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. **2008**, 47, 581-91		88

128	CD4+ T-regulatory cells: toward therapy for human diseases. *Immunological Reviews*, **2008**, 223, 391-421	11.3	194
127	How not to be seen: immune-evasion strategies in gene therapy. **2008**, 15, 239-46		29
126	Gene gun-mediated DNA vaccination enhances antigen-specific immunotherapy at a late preclinical stage of type 1 diabetes in nonobese diabetic mice. **2008**, 129, 49-57		34
125	Regulatory T cells in autoimmune endocrine diseases. **2008**, 19, 292-9		8
124	Reversal of new-onset type 1 diabetes in mice by syngeneic bone marrow transplantation. **2008**, 374, 282-7		19
123	Tr1 cells in the neat sighting-pole. **2008**, 27, 78-84		1
122	Polyclonal adaptive regulatory CD4 cells that can reverse type I diabetes become oligoclonal long-term protective memory cells. *Journal of Immunology*, **2008**, 181, 1798-805	5.3	37
121	(Xeno)estrogen regulation of food allergy. **2008**, 5, 259-70		
120	Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells. *Diabetes*, **2008**, 57, 2341-7	0.9	109
119	. **2008**,		
118	Re-establishing immune tolerance in type 1 diabetes via regulatory T cells. **2008**, 292, 174-83; discussion 183-6, 202-3		7
117	Immunotherapy with regulatory T cells in transplantation. **2009**, 1, 855-71		10
116	In vivo induction of type 1-like regulatory T cells using genetically modified B cells confers long-term IL-10-dependent antigen-specific unresponsiveness. *Journal of Immunology*, **2009**, 183, 8232-43	5.3	32
115	Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice. *Diabetes*, **2009**, 58, 875-81	0.9	34
114	Immune regulation by rapamycin: moving beyond T cells. **2009**, 2, pe25		35
113	An update on preventive and regenerative therapies in diabetes mellitus. **2009**, 121, 317-31		36
112	Therapeutic role of sirolimus in non-transplant kidney disease. **2009**, 123, 187-206		11
111	Allograft-specific cytokine profiles associate with clinical outcome after islet cell transplantation. **2009**, 9, 382-8		61

110	Use of a cocktail regimen consisting of soluble galectin-1, rapamycin and histone deacetylase inhibitor may effectively prevent type 1 diabetes. **2009**, 40, 424-6		6
109	The development and function of regulatory T cells. **2009**, 66, 2603-22		196
108	Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation. *Clinical and Experimental Immunology*, **2009**, 156, 141-8	6.2	33
107	Immunoregulatory functions of mTOR inhibition. *Nature Reviews Immunology*, **2009**, 9, 324-37	36.5	638
106	Autoimmune diabetic patients undergoing allogeneic islet transplantation: are we ready for a regulatory T-cell therapy?. **2009**, 127, 1-7		11
105	Dysfunction of IL-10-producing type 1 regulatory T cells and CD4(+)CD25(+) regulatory T cells in a mimic model of human multiple sclerosis in Cynomolgus monkeys. **2009**, 9, 599-608		37
104	Medical bioremediation of age-related diseases. **2009**, 8, 21		14
103	Is there a feudal hierarchy amongst regulatory immune cells? More than just Tregs. **2009**, 11, 237		10
102	Dendritic Cells. **2009**,		2
101	Use of rapamycin in the induction of tolerogenic dendritic cells. **2009**, 215-32		55
100	The honeymoon phase: intersection of metabolism and immunology. **2009**, 16, 286-92		44
99	Type 1 regulatory T cells are associated with persistent split erythroid/lymphoid chimerism after allogeneic hematopoietic stem cell transplantation for thalassemia. **2009**, 94, 1415-26		53
98	Inhibitors of the mammalian target of rapamycin and transplant tolerance. **2009**, 87, S27-9		8
97	Targeting of IL-2 receptor with a caspase fusion protein disrupts autoimmunity in prediabetic and diabetic NOD mice. **2010**, 53, 356-68		20
96	Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation. **2010**, 220, 52-63		75
95	Control of Schistosoma mansoni egg-induced inflammation by IL-4-responsive CD4(+)CD25(-)CD103(+)Foxp3(-) cells is IL-10-dependent. **2010**, 40, 2837-47		22
94	Reversal of type 1 diabetes by a new MHC II-peptide chimera: "Single-epitope-mediated suppression" to stabilize a polyclonal autoimmune T-cell process. **2010**, 40, 2277-88		16
93	Novel role of plasmacytoid dendritic cells in humans: induction of interleukin-10-producing Treg cells by plasmacytoid dendritic cells in patients with rheumatoid arthritis responding to therapy. **2010**, 62, 53-63		61

92	Anti-CD154 mAb and rapamycin induce T regulatory cell mediated tolerance in rat-to-mouse islet transplantation. **2010**, 5, e10352		31
91	Antigen-specific dependence of Tr1-cell therapy in preclinical models of islet transplant. *Diabetes*, **2010**, 59, 433-9	0.9	60
90	RNA interference screen in primary human T cells reveals FLT3 as a modulator of IL-10 levels. *Journal of Immunology*, **2010**, 184, 685-93	5.3	21
89	Autoantigens plus interleukin-10 suppress diabetes autoimmunity. **2010**, 12, 649-61		12
88	Suppression and Regulation of Immune Responses. *Methods in Molecular Biology*, **2011**,	1.4	5
87	Adoptive transfer of CD4+CD25+ regulatory cells combined with low-dose sirolimus and anti-thymocyte globulin delays acute rejection of renal allografts in Cynomolgus monkeys. **2011**, 11, 618-29		36
86	All creatures great and small: regulatory T cells in mice, humans, dogs and other domestic animal species. **2011**, 11, 576-88		38
85	Immune intervention with T regulatory cells: past lessons and future perspectives for type 1 diabetes. **2011**, 23, 182-94		40
84	Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B. **2011**, 2, 244		30
83	IL-1β promotes TGF-β and IL-2 dependent Foxp3 expression in regulatory T cells. **2011**, 6, e21949		15
82	Rapamycin combined with anti-CD45RB mAb and IL-10 or with G-CSF induces tolerance in a stringent mouse model of islet transplantation. **2011**, 6, e28434		33
81	mTOR signaling and metabolic regulation of T cells: new potential therapeutic targets in autoimmune diseases. **2011**, 17, 3888-97		24
80	Clinical tolerance in allogeneic hematopoietic stem cell transplantation. *Immunological Reviews*, **2011**, 241, 145-63	11.3	60
79	Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetes. **2011**, 139, 290-301		22
78	Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome. **2011**, 41, 1120-31		59
77	The evolving role of mTOR inhibition in transplantation tolerance. **2011**, 22, 408-15		42
76	Regulatory T cells require mammalian target of rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice. *Journal of Immunology*, **2011**, 186, 2809-18	5.3	53
75	Potential of T-regulatory cells to protect xenografts. **2012**, 17, 155-61		16

74	Tregs: application for solid-organ transplantation. **2012**, 17, 34-41		38
73	Adoptive transfer with in vitro expanded human regulatory T cells protects against porcine islet xenograft rejection via interleukin-10 in humanized mice. *Diabetes*, **2012**, 61, 1180-91	0.9	57
72	Targeting Janus tyrosine kinase 3 (JAK3) with an inhibitor induces secretion of TGF-by CD4+ T cells. **2012**, 9, 350-60		10
71	Isolation, expansion and functional assessment of CD4+CD25+FoxP3+ regulatory T cells and Tr1 cells from uremic patients awaiting kidney transplantation. **2012**, 26, 27-33		17
70	Historical overview of immunological tolerance. **2012**, 4, a006908		30
69	Intracellular metabolic pathways control immune tolerance. **2012**, 33, 1-7		53
68	An oral CD3-specific antibody suppresses T-cell-induced colitis and alters cytokine responses to T-cell activation in mice. **2012**, 143, 1298-1307		28
67	Rapamycin causes upregulation of autophagy and impairs islets function both in vitro and in vivo. **2012**, 12, 102-14		71
66	A comprehensive review of the phenotype and function of antigen-specific immunoregulatory double negative T cells. *Journal of Autoimmunity*, **2013**, 40, 58-65	15.5	66
65	T-cell-based immunotherapy of autoimmune diseases. **2013**, 12, 297-310		18
64	Modulation of TSC-mTOR signaling on immune cells in immunity and autoimmunity. **2014**, 229, 17-26		27
63	Prevention of type 1 diabetes through infection with an intestinal nematode parasite requires IL-10 in the absence of a Th2-type response. **2013**, 6, 297-308		63
62	STAT6 controls the number of regulatory T cells in vivo, thereby regulating allergic lung inflammation. *Journal of Immunology*, **2013**, 191, 1517-28	5.3	22
61	Obtaining regulatory T cells from uraemic patients awaiting kidney transplantation for use in clinical trials. *Clinical and Experimental Immunology*, **2013**, 173, 310-22	6.2	13
60	Transplant tolerance to pancreatic islets is initiated in the graft and sustained in the spleen. **2013**, 13, 1963-75		35
59	CD55 costimulation induces differentiation of a discrete T regulatory type 1 cell population with a stable phenotype. *Journal of Immunology*, **2013**, 191, 5895-903	5.3	25
58	Prostaglandin E2 potentiates mesenchymal stem cell-induced IL-10+IFN-CD4+ regulatory T cells to control transplant arteriosclerosis. *Journal of Immunology*, **2013**, 190, 2372-80	5.3	84
57	Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes. *Diabetes*, **2013**, 62, 3120-31	0.9	35

56	Foxp3+ Treg expanded from patients with established diabetes reduce Helios expression while retaining normal function compared to healthy individuals. **2013**, 8, e56209		23
55	Beneficial role of rapamycin in experimental autoimmune myositis. **2013**, 8, e74450		23
54	Therapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetes. **2013**, 8, e77296		17
53	The mouse idd2 locus is linked to the proportion of immunoregulatory double-negative T cells, a trait associated with autoimmune diabetes resistance. *Journal of Immunology*, **2014**, 193, 3503-12	5.3	12
52	Modulation of the pancreatic islet-stress axis as a novel potential therapeutic target in diabetes mellitus. **2014**, 95, 195-222		6
51	Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications. **2014**, 380, 39-68		161
50	Animal Models of Organ-Specific Autoimmune Disease. **2014**, 435-448		
49	Type 1 regulatory T cells specific for collagen type II as an efficient cell-based therapy in arthritis. **2014**, 16, R115		30
48	Retinoic acid stabilizes antigen-specific regulatory T-cell function in autoimmune hepatitis type 2. *Journal of Autoimmunity*, **2014**, 53, 26-32	15.5	23
47	Immune Depletion in Combination with Allogeneic Islets Permanently Restores Tolerance to Self-Antigens in Diabetic NOD Mice. **2015**, 10, e0142318		3
46	mTOR signaling in T cell immunity and autoimmunity. **2015**, 34, 50-66		44
45	Regulatory T Cell Immunotherapy in Immune-Mediated Diseases. *Current Stem Cell Reports*, **2015**, 1, 177-186		10
44	Congenital Immunodeficiency Diseases. **2016**, 45-81		
43	Inducing and Administering Tregs to Treat Human Disease. *Frontiers in Immunology*, **2015**, 6, 654	8.4	37
42	Regulatory mechanisms of immune tolerance in type 1 diabetes and their failures. *Journal of Autoimmunity*, **2016**, 71, 69-77	15.5	17
41	The influence of skin microorganisms on cutaneous immunity. *Nature Reviews Immunology*, **2016**, 16, 353-66	36.5	145
40	Rapamycin/GABA combination treatment ameliorates diabetes in NOD mice. *Molecular Immunology* , **2016**, 73, 130-7	4.3	16
39	Concise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 Diabetes. *Stem Cells*, **2016**, 34, 809-19	5.8	10

38	Role of Metabolism in the Immunobiology of Regulatory T Cells. *Journal of Immunology*, **2016**, 197, 2567-75	5.3	71
37	mTOR inhibitors effects on regulatory T cells and on dendritic cells. *Journal of Translational Medicine*, **2016**, 14, 152	8.5	39
36	Accessory cells for cell transplantation. *Diabetes, Obesity and Metabolism*, **2016**, 18, 115-24	6.7	16
35	Rapamycin Augments Immunomodulatory Properties of Bone Marrow-Derived Mesenchymal Stem Cells in Experimental Autoimmune Encephalomyelitis. *Molecular Neurobiology*, **2017**, 54, 2445-2457	6.2	18
34	Controlled Release of Second Generation mTOR Inhibitors to Restrain Inflammation in Primary Immune Cells. *AAPS Journal*, **2017**, 19, 1175-1185	3.7	8
33	Immunotherapy in Autoimmune Diabetes. **2017**,		1
32	B polyunsaturated fatty acids ameliorate type 1 diabetes and autoimmunity. *Journal of Clinical Investigation*, **2017**, 127, 1757-1771	15.9	59
31	The Induction and Maintenance of Transplant Tolerance Engages Both Regulatory and Anergic CD4 T cells. *Frontiers in Immunology*, **2017**, 8, 218	8.4	19
30	Functional Defects of Treg Cells: New Targets in Rheumatic Diseases, Including Ankylosing Spondylitis. *Current Rheumatology Reports*, **2018**, 20, 30	4.9	18
29	Role of TGF- In Self-Peptide Regulation of Autoimmunity. *Archivum Immunologiae Et Therapiae Experimentalis*, **2018**, 66, 11-19	4	7
28	The Interleukin (IL)-23/T helper (Th)17 Axis in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. *Cold Spring Harbor Perspectives in Medicine*, **2018**, 8,	5.4	14
27	Harnessing the power of regulatory T-cells to control autoimmune diabetes: overview and perspective. *Immunology*, **2018**, 153, 161-170	7.8	38
26	The Biology of T Regulatory Type 1 Cells and Their Therapeutic Application in Immune-Mediated Diseases. *Immunity*, **2018**, 49, 1004-1019	32.3	123
25	Transcriptional Programs Underlying Cd4 T Cell Differentiation and Functions. *International Review of Cell and Molecular Biology*, **2018**, 341, 1-61	6	6
24	Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside. *Frontiers in Immunology*, **2018**, 9, 303	8.4	12
23	Targeting Stem Cell-Derived Tissue-Associated Regulatory T Cells for Type 1 Diabetes Immunotherapy. *Current Diabetes Reports*, **2019**, 19, 89	5.6	5
22	Reversal of New Onset Type 1 Diabetes by Oral -Based Combination Therapy and Mediated by Regulatory T-Cells in NOD Mice. *Frontiers in Immunology*, **2019**, 10, 320	8.4	10
21	Restoring self-tolerance in autoimmune diseases by enhancing regulatory T-cells. *Cellular Immunology*, **2019**, 339, 41-49	4.4	18

20	Key role of macrophages in tolerance induction via T regulatory type 1 (Tr1) cells. *Clinical and Experimental Immunology*, **2020**, 201, 222-230	6.2	5
19	The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases. *Frontiers in Immunology*, **2020**, 11, 472	8.4	9
18	Rapamycin Plus Vildagliptin to Recover Cell Function in Long-Standing Type 1 Diabetes: A Double-Blind, Randomized Trial. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e507-e519	5.6	3
17	Biologia Futura: Emerging antigen-specific therapies for autoimmune diseases. *Biologia Futura*, **2021**, 72, 15-24	1	0
16	Mitochondrial-encoded MOTS-c prevents pancreatic islet destruction in autoimmune diabetes. *Cell Reports*, **2021**, 36, 109447	10.6	4
15	Improving the Efficacy of Regulatory T Cell Therapy. *Clinical Reviews in Allergy and Immunology*, **2021**, 1	12.3	4
14	Isolation, expansion, and characterization of human natural and adaptive regulatory T cells. *Methods in Molecular Biology*, **2007**, 380, 83-105	1.4	33
13	Natural and induced T CD4+CD25+FOXP3+ regulatory T cells. *Methods in Molecular Biology*, **2011**, 677, 3-13	1.4	21
12	Methods for in vitro generation of human type 1 regulatory T cells. *Methods in Molecular Biology*, **2011**, 677, 31-46	1.4	27
11	The cross-regulatory relationship between human dendritic and regulatory T cells and its role in type 1 diabetes mellitus. *Review of Diabetic Studies*, **2007**, 4, 68-76	3.6	7
10	Human Type 1 T Regulatory Cells. **2008**, 455-471		
9	Activation pathways that drive CD4 T cells to break tolerance in autoimmune diseases.. *Immunological Reviews*, **2022**,	11.3	1
8	Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1.. *International Journal of Molecular Sciences*, **2021**, 23,	6.3	0
7	Presentation_1.pdf. **2019**,		
6	New Developments in T Cell Immunometabolism and Therapeutic Implications for Type 1 Diabetes. *Frontiers in Endocrinology*, 13,	5.7	
5	Alteration of interleukin-10-producing Type 1 regulatory cells in autoimmune diseases. *Current Opinion in Hematology*, **2022**, 29, 218-224	3.3	2
4	Immunological balance between Treg and Th17 lymphocytes as a key element of type 1 diabetes progression in children. 13,		1
3	Type 1 regulatory T cell-mediated tolerance in health and disease. 13,		0

2	Erratum: Type 1 regulatory T cell-mediated tolerance in health and disease. 13,	0
1	Highly purified and functionally stable in vitro expanded allospecific Tr1 cells expressing immunosuppressive graft-homing receptors as new candidates for cell therapy in solid organ transplantation. 14,	0